DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Haloperidol is a drug marketed by Alpharma, Lannett Co Inc, Morton Grove, Pharm Assoc, SCS, Teva, Teva Pharms, Abraxis Pharm, Akorn, Baxter Hlthcare Corp, Fosun Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma Pharms, Marsam Pharms Llc, Mylan Labs Ltd, Sagent Pharms, Smith And Nephew, Solopak, Teva Pharms Usa, Watson Labs, Cycle Pharms Ltd, Duramed Pharms Barr, Innogenix, Lederle, Mylan, Par Pharm, Purepac Pharm, Quantum Pharmics, Royce Labs, Sandoz, Upsher Smith Labs, Vintage, Zydus Pharms Usa, Hong Kong, Hospira, Sandoz Inc, Somerset Theraps Llc, West-ward Pharms Int, Zydus Pharms, and Actavis Mid Atlantic. and is included in one hundred and six NDAs.
The generic ingredient in HALOPERIDOL is haloperidol decanoate. There are twenty drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the haloperidol decanoate profile page.
A generic version of HALOPERIDOL was approved as haloperidol decanoate by FRESENIUS KABI USA on December 19th, 1997.
Summary for HALOPERIDOL
|Finished Product Suppliers / Packagers:||29|
|Raw Ingredient (Bulk) Api Vendors:||108|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for HALOPERIDOL|
|What excipients (inactive ingredients) are in HALOPERIDOL?||HALOPERIDOL excipients list|
|DailyMed Link:||HALOPERIDOL at DailyMed|
Recent Clinical Trials for HALOPERIDOL
Identify potential brand extensions & 505(b)(2) entrants
|Ottawa Hospital Research Institute||Phase 1/Phase 2|
|Foothills Medical Centre||Phase 1/Phase 2|
|Providence Hospital||Phase 1/Phase 2|
Pharmacology for HALOPERIDOL
|Drug Class||Typical Antipsychotic |